Peptidetesting

Understand testing before you trust it

Identity test: Is it really the peptide you ordered?

An HPLC purity certificate only tells you how much of a substance is in the sample - not what that substance is. To confirm its identity, you need mass spectrometry, which checks the molecular mass or the amino acid sequence.

HPLC Purity in Peptides: Why a Single Peak Isn't Enough

An HPLC purity certificate (high-performance liquid chromatography) tells you how large the main peak is compared to all other peaks. This method separates substances in a sample and answers the question of how much of a single substance is present, but it does not provide proof of that substance's exact identity.

A peptide can have a purity of 98% and still be the wrong substance. In analytical chemistry, purity is considered necessary but not sufficient. Even a sharp peak at the expected retention time - the moment the substance exits the separation column - does not guarantee that it is the right molecule.

Confirming Peptide Identity: Mass Spectrometry and LC-MS/MS

The identity of a peptide is checked using mass spectrometry (MS), which measures the molecular mass. Common methods include ESI-MS (electrospray ionization), MALDI-TOF (laser desorption with time-of-flight analyzer), and LC-MS/MS (liquid chromatography with tandem mass spectrometry).

While ESI-MS generates multiply charged ions of the peptide that produce a characteristic pattern, and MALDI-TOF simply confirms the molecular mass, LC-MS/MS is considered the gold standard. This method directly verifies the amino acid sequence and rules out isobaric peptides - those that have the same mass but a different structure.

Dangers in the Gray Market: Documented Mislabeling of Peptides

Reports on laboratory analyses of peptide vials show that nearly 30% of samples had issues such as contamination. These data come from a television report about a commercial laboratory and summarize various analytical problems, but they do not constitute a peer-reviewed scientific study.

Scientific literature and regulatory authorities warn of a growing market for counterfeit peptide biopharmaceuticals, including substances in preclinical or clinical development. The risk of substitution is real: a vial can contain a completely different peptide than the label promises, even if the content is highly pure.

Limits of Identity Testing: What a Result Tells You

An identity result confirms that the molecular mass (via MS) or the amino acid sequence (via LC-MS/MS) matches the target peptide. It rules out major synthesis errors, but it does not provide information about purity, the actual content of the active substance, or safety-relevant residues.

For a complete picture, further analyses are needed: RP-HPLC for purity, amino acid analysis for content, and the LAL test for endotoxins. Additionally, GC-MS checks for solvent residues, and ICP-MS checks for heavy metals or elemental impurities. An identity certificate only clarifies the 'what', not the safety or quantity.

COA Without Identity Proof: An Incomplete Analysis Certificate

An analysis certificate (COA) that only states HPLC purity leaves the identity of the substance unconfirmed. The ICH guidelines (International Council for Harmonisation) require two separate identification methods for peptide active ingredients, because a single measurement is often not enough for a definitive proof.

Without an identity method, a COA does not even meet the minimum standard. Given known cases of mislabeling in the gray market, a purity-only certificate offers no protection against mix-ups. A safe analysis package must include identity, purity, content, and safety as complementary tests.

Sources

  1. Regulatory Guidelines for the Analysis of Therapeutic Peptides and Proteins
  2. Reference Standards to Support Quality of Synthetic Peptide ... - PMC
  3. What Are the FDA Requirements for Peptide Characterization? -
  4. Q 6 A Specifications: Test Procedures and Acceptance Criteria for New ...
  5. ICH Q6A specifications: test procedures and acceptance criteria for new drug substances and new drug products: chemical substances - Scientific guideline | European Medicines Agency (EMA)
  6. Peptides: Lab finds risks, problems in 30% of vials tested – NBC4 Washington
  7. FDA Enforcement Actions Against Peptide Sellers: Case Studies - PeptideLaws.com
  8. Guideline on the Development and Manufacture of Synthetic Peptides
  9. Development of an LC-MS/MS peptide mapping protocol for the NISTmAb
  10. The sentinel role of forensic toxicology laboratories to identify and act upon diverse drug threats by addressing toxicology and economic demands - PMC
  11. Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances | FDA
  12. draft-guideline-development-manufacture-synthetic ... - EMA
  13. A comparison of MS/MS-based, stable-isotope-labeled, quantitation performance on ESI-quadrupole TOF and MALDI-TOF/TOF mass spectrometers - PubMed
  14. Identification of dipeptides by MALDI-ToF mass spectrometry in long-processing Spanish dry-cured ham - PMC
  15. LESSONS IN DE NOVO PEPTIDE SEQUENCING BY TANDEM MASS SPECTROMETRY
  16. Characterization of Synthetic Peptide Therapeutics Using Liquid Chromatography-Mass Spectrometry: Challenges, Solutions, Pitfalls, and Future Perspectives - PubMed
  17. Peptide Purity Testing: How to Verify Quality and Safety (2026 Guide)
  18. LC-MS Peptide Identity | Mass Spectrometry Guide | American Peptides
  19. Analysis of illegal peptide biopharmaceuticals frequently encountered by controlling agencies
  20. Analytical Services: HPLC and Mass Spectrometry for Peptide Validation
  21. Q6A guideline
  22. Mass Spectrometry for Peptide Identity Verification: ESI-MS, MALDI-TOF ...
  23. Control Strategies for Synthetic Therapeutic Peptide APIs - Part I
  24. Peptide purity standards: HPLC, mass spec, and what >98 ...